Erectile dysfunction: an underdiagnosed condition associated with multiple risk factors

References

• NIH Consensus Development Panel on Impotence. NIH Consensus Conference. Impotence. J Am Med Assoc 1993;270:83–90
   PubMed Web of Science ®Google Scholar
• Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995;22:699–709
   PubMed Web of Science ®Google Scholar
• Rosen RC, Fisher W, Eardley I, Niederberger C, Nadal A, Sand M. The multinational men’s attitudes to life events and sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20(5):[this issue]
   Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Ageing Study. J Urol 1994;151:54–61
   Google Scholar
• Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000;12:305–11
   PubMed Web of Science ®Google Scholar
• Vale J. Benign prostatic hyperplasia and erectile dysfunction – is there a link? Curr Med Res Opin 2000;16(Suppl. 1):s63–s68
   Google Scholar
• Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The Multinational Survey of the Ageing Male (MSAM-7). Eur Urol 2003;44:637–49
   PubMed Web of Science ®Google Scholar
• Tubaro A, Polita M, Giambroni L, et al. Sexual function in patients with LUTS suggestive of BPH. Eur Urol 2001;40(Suppl. 1):19–22
   Google Scholar
• Namasivayam S, Minhas S, Brooke J, et al. The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol 1998;82:842–6
   PubMedGoogle Scholar
• Boyle P, Robertson C, Mazzetta C, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres. The UrEpik study. Br J Urol Int 2003;92:719–25
   Web of Science ®Google Scholar
• Khan MA, Thompson CS, Dashwood MR, Mumtaz FH, Morgan RJ, Mikhailidis DP. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outflow obstruction. Curr Vasc Pharmacol 2003;1:27–31
   PubMedGoogle Scholar
• Lukacs B, Grange JC, Comet D, the BPM Group in General Practice. One year follow up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health related QoL questionnaire. Urology 2000;55: 540–6
   Google Scholar
• Kirby, RS, Anderson M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. Br J Urol Int 2001;87:192–200
   Google Scholar
• Palacio A, Batista JE, Torrubia R, et al. Tamsulosin: effect on sexual function in almost 3000 patients with LUTS managed in real life practice in Spain. Br J Urol 2000;86(Suppl. 3):32–3
   Google Scholar
• Debruyne FMJ. Alpha-blockers: are all created equal? Urology 2000;56(Suppl. 5A):20–2
   Google Scholar
• Uygur MC, Gur E, Arik AI, et al. Erectile dysfunction following treatments of benign prostatic hyperplasia: a prospective study. Andrologia 1998;30:5–10
   PubMed Web of Science ®Google Scholar
• Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. Br J Urol Int 2002;90:836–9
   Google Scholar
• Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999;57:967–89
   PubMed Web of Science ®Google Scholar
• McMahon CG, Samali R, Johnson H. Efficacy, safety, and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000;164;1192–6
   Google Scholar
• Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. New Eng J Med 1998;338:1397–404
   PubMed Web of Science ®Google Scholar
• Palumbo F, Bettocchi C, Selvaggi FP, Pryor JP, Ralph DJ. Sildenafil: efficacy and safety in daily clinical experience. Eur Urol 2001;40:176–80
   Google Scholar
• Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montosori F. A 4-year update on the safety of sildenafil citrate. Urology 2002;60(2 Suppl 2):S42–S47
   Google Scholar
• El-Galley R, Rutland H, Talic R, Keane T, Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001;166:927–31
   Google Scholar
• Sheu JY, Chen KK, Lin ATL, et al. Long-term efficacy and safety of sildenafil for patients with erectile dysfunction J Chin Med Assoc 2003;66:480–6
   Google Scholar
• Mumtaz FH, Khan MA, Mikhailidis DP, Morgan RJ. Re; long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2002;168:206
   PubMed Web of Science ®Google Scholar
• Tomera K. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2002;168:206
   PubMed Web of Science ®Google Scholar
• Kuthe A. Phosphodiesterase % inhibitors in male sexual dysfunction. Curr Opin Urol 2003;13:405–10
   PubMed Web of Science ®Google Scholar
• Monga M, Bettencourt R, Barrett-Conner E. Community based study of erectile dysfunction and sildenafil use: the Rancho Bernardo Study. Urology 2002;59:753–7
   Google Scholar
• Perimenis P, Gyftopoulos K, Giannitsas K, et al. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 2004;16:2–7
   PubMed Web of Science ®Google Scholar
• Khan MA, Morgan RJ, Mikhailidis DP. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002;18:103–7
   PubMed Web of Science ®Google Scholar
• Mayoux E, Ramirez JF, Pouyet T, Barras M, Arbilla S, Galzin AM. Alfuzosin improves penile erection triggered by apomorphine in spontaneous hypertensive rats. Eur Urol 2004;45:110–6
   PubMed Web of Science ®Google Scholar